Safety
-
Temodar (temozolomide) capsules and for injection
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2010
ADVERSE REACTIONS
Postmarketing Experience
- Cases of interstitial pneumonitis/pneumonitis, alveolitis, and pulmonary fibrosis have been reported.
-
-







